- Home
- DTST vs INM Comparison
DTST vs INM Comparison
Compare DTST & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | INM |
|---|---|---|
| Founded | 2001 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.1M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTST | INM |
|---|---|---|
| Price | $3.00 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.1K | ★ 35.5K |
| Earning Date | 11-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3671.43 | 62.68 |
| EPS | ★ N/A | N/A |
| Revenue | $1,382,929.00 | ★ $4,942,633.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $20.00 | $26.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $2.75 | $0.58 |
| 52 Week High | $5.15 | $2.33 |
Technical Indicators
Market Signals| Indicator | DTST | INM |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 51.48 |
| Support Level | $2.82 | $1.35 |
| Resistance Level | $3.15 | $1.44 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 17.53 | 38.46 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.